COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00005962
Recruitment Status : Completed
First Posted : November 5, 2003
Last Update Posted : August 20, 2013
National Cancer Institute (NCI)
Information provided by:
Eastern Cooperative Oncology Group

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : October 2005
Actual Study Completion Date : June 2007
Publications of Results:
Litzow MR, Goloubeva O, Rowe J, et al.: A randomized phase II trial of gemtuzumab ozogamicin vs. liposomal daunorubicin vs. cyclophosphamide plus topotecan, each combined with intermediate dose Ara-C for the treatment of patients with relapsed or refractory acute myelogenous leukemia . [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-2359, 2003.